Case 2: Weight Gain With ART - Challenging Cases - Video Modules - HIV Annual Update 2021 - HIV

Case 2: Patient Gaining Weight on DTG + FTC/TAF

In this on-demand webcast of a live roundtable, expert faculty consider the integrated approaches needed to address barriers to ART adherence and to select an effective new regimen for an older man with long-standing HIV infection, several comorbidities, and a complex treatment history with multiclass drug resistance. Then the expert panel discusses the best management strategies for a patient who is gaining excess weight on an INSTI- and TAF-containing first-line regimen.

Babafemi Taiwo, MBBS
Program Director

Rajesh T. Gandhi, MD

Daniel R. Kuritzkes, MD

Released: October 29, 2021

Information on this Educational Activity

Program Director

Babafemi Taiwo, MBBS

Gene Stollerman Professor of Medicine
Chief, Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV and funds for research support from Janssen.

Faculty

Rajesh T. Gandhi, MD

Professor of Medicine
Department of Infectious Diseases
Harvard Medical School
Physician, Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Rajesh T. Gandhi, MD, has disclosed that he has received consulting fees from Merck.

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has disclosed that he has received funds for research support rom Atea, Gilead Sciences, Merck, Novartis, and ViiV and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Edward King, MA

Executive Vice President

Edward King, MA, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Sarah Anderson, PharmD

Scientific Director

Sarah L. Anderson, PharmD, BCACP, BCPS, FASHP, FCCP, has no relevant conflicts of interest to report.

Target Audience

This program is intended for pathologists and other healthcare providers who treat and manage patients with lung cancer.

Goal

The goal of this activity is to improve participants’ knowledge of and competence in assessing biomarkers to guide the use of immune checkpoint inhibitors in the treatment of patients with lung cancer.

Program Medium

This program has been made available online.

Slides on Key Decisions in HIV Care: Renal and Hepatic Considerations in Older PWH

View Slideset

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS

Jens D. Lundgren, MD, DMSc Released: January 13, 2022

ClinicalThought

Patient Perspective: Managing the Effects of Long-term HIV, ART, and Aging

View ClinicalThought

Clinical Care Options (CCO) presents a woman’s perspective on managing the long-term effects of HIV, antiretroviral therapy, and aging

Anonymous Patient Released: January 11, 2022

Multimedia

NASH and HIV: How to Diagnose

View Multimedia

From Clinical Care Options (CCO) and Dr. Jürgen K. Rockstroh and Dr. Giada Sebastiani: Recommended approach for screening and diagnosing NASH in patients with HIV.